Spots Global Cancer Trial Database for A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
Official Title: A Prospective Study of Bortezomib Combined With CHEP Regimen in the Treatment of Primary Peripheral T Cell Lymphoma
Study ID: NCT04061772
Conditions
Study Description
Brief Summary: To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma
Detailed Description: The purpose of this study was to evaluate the efficacy and safety of bortezomib combined with CHEP in patients with peripheral T cell lymphoma. Primary end point of this study were objective response rate including complete remission rate and partial remission rate.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Contact Details
Name: Ming Chen, PhD
Affiliation: Zhejiang Cancer Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
